Vascular Biogenics Ltd (VBLT)

[mantoo123]

Thank you for the presentation link.

The "SCO 2017 – Highlighted Company Presentations #2" by LifeSci Capital [1] which you mentioned earlier is noteworthy, in particular the sentence:

Notably, patients in the continuous exposure group had an overall lower Karnofsky performance status (KPS), a less successful initial resection, and had a higher rate of second recurrence than the limited exposure group at baseline, increasing our confidence in the prior survival results with VB-111. Patient baseline characteristics are depicted in Figure 1.

VB-111 seems to be fighting with one hand tied behind its back and still bringing in better results.


[1] http://www.lifescicapital.com/wp-content/uploads/LSC-ASCO2017%E2%80%93Highlighted-Company-Presentations2.pdf